AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01901601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femtosecond laser
Description: The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
Study NCT03081390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation testing
Description: At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
Study NCT02065375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Ophthalmic Suspension 1.0%
Study NCT02065375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Opthalmic Suspension 0.5%
Study NCT02065375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02838914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation (RFCA)
Description: Patients undergo radiofrequency ablation (RFCA)
Study NCT02040857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4/6 inhibitor
Study NCT02040857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Endocrine Therapy
Study NCT00091247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline hydrochloride
Study NCT00091247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02418247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I131
Study NCT02418247 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: I123
Study NCT03648112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 1
Description: The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.
Study NCT03648112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 2
Description: The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.
Study NCT03648112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 3
Description: The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.
Study NCT03648112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 4
Description: The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.
Study NCT03648112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread.
Study NCT00526630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (MPD)
Description: Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
Study NCT00526630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given placebo instead of active MPD.
Study NCT03577067 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection for primary and secondary disease
Description: Liver resection in parenchyma-sparing setting for primary and secondary disease
Study NCT04123678 — intervention group
Intervention type: DEVICE
Intervention: Deep Ensemble for the Recognition of Malignancy (DERM)
Description: AI-based decision support tool
Study NCT03631446 — intervention group
Intervention type: DRUG
Intervention: Sodium Picosulfate, Magnesium Oxide and Citric Acid
Description: Combination powder for oral solution
Study NCT02697279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Incision and Drainage.
Description: Control Group- Standard treatment of a simple cutaneous abscess with traditional I\&D technique with or without packing utilizing a standard I\&D kit.
Study NCT02697279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop drainage
Description: Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I\&D kit and the cuff of a sterile glove for a loop device.
Study NCT01755442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
Study NCT01755442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
Study NCT00593567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin-collagen sponge
Description: Inserted daily into open ulcer
Study NCT00593567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: 750mg oral levofloxacin daily
Study NCT02244905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Deviance
Description: The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
Study NCT02244905 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard-of-Care Infection Control approach
Description: Standard-of-Care Infection Control approach
Study NCT02244905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care Infection Control approach
Description: Standard-of-Care Infection Control approach
Study NCT00590902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774: erlotinib, TarcevaTM
Description: 150 mg, 100 mg and 25 mg tablets
Study NCT01245465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Profermin
Description: Medical Food (food for special medical purposes)
Study NCT00633815 — intervention group
Intervention type: OTHER
Intervention: Supine positioning
Description: Subjects underwent exercise testing on a stationary bicycle in the supine position
Study NCT00633815 — intervention group
Intervention type: OTHER
Intervention: Upright positioning
Description: Subjects underwent exercise testing on a stationary bicycle in the upright position
Study NCT02643576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F&V Bonus
Description: To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
Study NCT04342637 — intervention group
Intervention type: OTHER
Intervention: Practice details
Description: Physicians will report details of their endoscopy practice through answering the questions of the questionnaire
Study NCT00119717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroFlo™ catheter
Description: 45 minute treatment
Study NCT00119717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: ASA Guidelines
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: Specified dose on specified days
Study NCT02643576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restriction
Description: To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
Study NCT02643576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bonus & Restriction
Description: To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
Study NCT03713528 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intraoperative Intraosseous Vancomycin
Description: After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Specified dose on specified days
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Specified dose on specified days
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Specified dose on specified days
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Specified dose on specified days
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Specified dose on specified days
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Specified dose on specified days
Study NCT03131973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Specified dose on specified days
Study NCT01339923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
Study NCT01339923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: 2 doses (3.5, 5 months of age) plus booster (11 months of age)
Study NCT01339923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: 2 doses (6, 8 months of age) plus booster (11 months of age)
Study NCT01560325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-516 inj.
Description: CKD-516: 3.3\~13mg/m2/day
Study NCT02352597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phytoestrogen
Description: 20mg of cimifuga racemosa from day 1- 12
Study NCT02352597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: 2mg from cycle day 7 to day 11
Study NCT02352597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: 50 mg orally every 8 hours started from cycle day 3 for 5 days
Study NCT01920282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Study NCT01694615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprobe biopsy
Study NCT01694615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps Biopsy
Study NCT00003213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 4 mg Dexamethasone in the morning
Study NCT00003213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron hydrochloride
Description: 1 mg Granisetron in the morning
Study NCT00003213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide hydrochloride
Description: 20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
Study NCT00582036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Description: Use of sliding scale insulin as per Appendix 1
Study NCT00582036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deployment of the MiniMed Paradigm monitoring device
Description: Automated insulin delivery system
Study NCT02484820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone pessary
Description: Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
Study NCT01339923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: 2 doses 2 months apart
Study NCT01920282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Study NCT01454700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)
Description: Randomization to 12 months with CSII plus CGM
Study NCT01454700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Description: Randomization12 months therapy with MDI
Study NCT01290393 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
Study NCT01153061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fistula closure with Gore Helex Septal Occluder
Description: The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
Study NCT01153061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore Helex Septal Occluder
Description: Fistula closure with endoscopic release of occluder in the fistula traject.
Study NCT00788190 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Distal Radius Fracture Reduction
Description: Surgical Intervention to Reduce Distal Radius Fracture
Study NCT00788190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative Management
Description: Conservative management of Distal Radius Fractures
Study NCT01305083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Udenafil
Description: Placebo-control
Study NCT01305083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil
Description: Placebo-control
Study NCT01305083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01305083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02494128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education in group leadership
Study NCT01048333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol Turbuhaler 9 μg and Placebo Diskus
Study NCT01339923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C oligosaccharide conjugated vaccine
Description: Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
Study NCT01339923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
Description: Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
Study NCT01920282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebivolol plus Lifestyle Modification
Study NCT01339923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: Schedule 3, 5, 12 rMenB + OMV vaccine
Study NCT01339923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: Schedule 13,15 rMenB + OMV vaccine
Study NCT01163968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMENTUM
Description: The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
Study NCT03040804 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose Radiotherapy
Description: Subjects in this protocol will only receive radiotherapy directed at one region, typically the region that is most bothersome to the patient. Patients will receive a total radiotherapy dose 7.5 Gy in five daily fractions of 1.5 Gy.
Study NCT00459290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Study NCT01017523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone support and behavior change
Description: Diabetes self-management education provided over the telephone either for individual or couples
Study NCT01017523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone support and behavior change
Description: Diabetes self-management education provided over the telephone either for individual or couples
Study NCT01017523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diabetes self-management education
Description: Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
Study NCT03718520 — intervention group
Intervention type: OTHER
Intervention: no intervention, this is a purely observational study
Description: No intervention
Study NCT01993901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSRT led telephone follow up
Description: Patients in the intervention group will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms. A second follow up telephone call will be made at 12 weeks post treatment if required in order to address treatment related side effects that were identified during the first call and any interventions that were recommended
Study NCT03164278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Transfer Training
Description: Independent Transfer Training Program: ITTP training starts with an overview and self-evaluation using the transfer assessment instrument questionnaire (TAI-Q) followed by three core modules: wheelchair setup, body setup, and flight/landing. Wheelchair setup includes factors such as the angle and distance of the wheelchair to the transfer surface, removing barriers, applying the brakes, and height of the transfer. Body setup involves positioning one's body for an optimal transfer and covers foot, hip, arm and hand positions. Flight/landing discusses how to achieve a smooth and controlled transfer, the head-hips relationship, use of transfer device, and safe landing.
Study NCT04098393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
Study NCT04098393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan (70mg/m2/day) administered on days -6 and -5.
Study NCT04098393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Description: ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
Study NCT04098393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan 0.8 mg/kg
Description: Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
Study NCT04098393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (Allo-HCT)
Description: Allogeneic hematopoietic cell transplantation following the conditioning regimen.
Study NCT02775175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Ramadan Fasting
Description: The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
Study NCT00314548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGE1 (prostacyclin)
Description: alprostadil nebulization
Study NCT00314548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: nebulize for 30 mins
Study NCT00089141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Given orally
Study NCT00089141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally